Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SanofiNASDAQ: SNY
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of €2.23B rose 17.0% year over year, ahead of the +5.4% change in trailing-twelve-month research & development. Sequentially, it rose 27.8% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Research & development amounted to 16.8% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.0% holds above the trailing-twelve-month pace of +5.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 7.84B EUR
- Year-over-year change
- +6.1%
- 4-year CAGR
- +8.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.84B | +6.1% |
| FY2024 | 2024-12-31 | 7.39B | +13.6% |
| FY2023 | 2023-12-31 | 6.51B | +0.1% |
| FY2022 | 2022-12-31 | 6.5B | +14.2% |
| FY2021 | 2021-12-31 | 5.69B | — |
Research & Development vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.4% is the 8th highest of 11, against a peer median of +14.2%.
- Research & development amounts to 16.6% of revenue for SNY, versus a peer median of 20.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 58.11B DKK | +28.3% | +29.3% | 17.6% | |
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $14.6B USD | +23.4% | +22.9% | 18.3% | |
| LTM Jun 2026 | $11.28B USD | +9.2% | +5.4% | 20.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | $10.72B USD | +3.1% | +1.5% | 21.8% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Jun 2026 | €8.11B EUR | +5.4% | +6.5% | 16.6% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| LTM Jun 2026 | $6.07B USD | +2.7% | +5.2% | 19.9% | |
| Peer median (excluding SNY) | — | +14.2% | +8.3% | 20.2% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.18B | 40.56B | 41.62B | 44.29B | 46.72B |
| Cost of Revenue | 12.26B | 11.88B | 12.63B | 13.21B | 13.05B |
| Gross Profit | 26.92B | 28.68B | 28.99B | 31.08B | 33.67B |
| Gross Margin | 68.7% | 70.7% | 69.7% | 70.2% | 72.1% |
| Research & Development | 5.69B | 6.5B | 6.51B | 7.39B | 7.84B |
| Selling, General & Admin | 9.56B | 8.74B | 8.93B | 9.18B | 10.24B |
| Operating Expenses | 18.79B | 18.52B | 22.03B | 23.83B | 24.07B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| EBITDA | 11.54B | 13.51B | 11.39B | 11.03B | 12.48B |
| EBITDA Margin | 29.5% | 33.3% | 27.4% | 24.9% | 26.7% |
| Operating Income | 8.13B | 10.16B | 6.96B | 7.25B | 9.6B |
| Operating Margin | 20.7% | 25.1% | 16.7% | 16.4% | 20.5% |
| Interest Income | 3.13M | 168.96M | 530.5M | 457.53M | 331M |
| Interest Expense | 377.37M | 384.8M | 512.82M | 622.58M | 626M |
| Other Income / Expenses | (289M) | (170M) | (845M) | (494M) | (3.58B) |
| Income Before Tax | 7.84B | 9.99B | 6.12B | 6.76B | 6.02B |
| Pre-Tax Margin | 20.0% | 24.6% | 14.7% | 15.3% | 12.9% |
| Income Tax Expense | 1.56B | 1.91B | 1.02B | 1.2B | 1.04B |
| Net Income | 6.22B | 8.37B | 5.4B | 5.56B | 7.81B |
| Net Margin | 15.9% | 20.6% | 13.0% | 12.6% | 16.7% |
| EPS (Basic) | 2.49 | 3.19 | 2.15 | 2.19 | 3.20 |
| EPS (Diluted) | 2.49 | 3.18 | 2.15 | 2.19 | 3.20 |
| Weighted Avg Shares | 2.51B | 2.5B | 2.5B | 2.5B | 2.44B |
| Weighted Avg Shares (Diluted) | 2.51B | 2.5B | 2.51B | 2.5B | 2.44B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.